Progress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743)

Drugs of the Future

Volumn 21, Issue 11, 1996, Pages 1155-1165

  Jimeno, José M ^a   Faircloth, Glynn ^b   Cameron, Lewis ^a   Meely, Kathleen ^a   Vega, Eduardo ^a   Gómez, José M Andrés ^a   Sousa Faro, Fernández ^a   Rinehart, Kenneth ^c  

^a PHARMAMAR S A   (Spain)

^b PharmaMar USA Inc   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TRABECTEDIN;

ANTINEOPLASTIC ACTIVITY; CANCER; CELL CULTURE; DOG; DRUG ISOLATION; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; INVERTEBRATE; MARINE ENVIRONMENT; MONKEY; NONHUMAN; REVIEW; TUMOR CELL; XENOGRAFT;

EID: 0030453986     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.11.385487     Document Type: Review

References (65)

1. Chabner, B.A. Preface. In: Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd Edition. Chabner, B.A., Longo, D.L. (Eds.). Lippincott Raven: Philadelphia 1996, xi.
2. Buick, R.N. Cellular basis of chemotherapy. In: Cancer Chemotherapy Handbook, 2nd Edition. Dorr, R.T., Von Hoff, D.D. (Eds.). Appleton & Lange: New York 1994, 3-14.
3. Rosenberg, S.A. The management of Hodgkin's disease: Half a century of change. Ann Oncol 1996, 7: 555-60.
4. Rosell, R., Gómez-Codina, J., Camps, C. et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. New Engl J Med 1994, 330: 153-8.
5. Jimeno, J., Gravalos, L.G., de Quesada, T.G., Faircloth, G., Fernández-Puentes, J.L. Exploitation of marine microorganisms and invertebrates as a source to identify new anticancer compounds. Proc Conf Discovering Drugs from Nature: Novel Approaches and New Sources (Dec. 5, London) 1994.
6. Nicoletti, M.I., Garofalo, A., Lucchini, V. et al. Batimastat potentiates cisplatin activity on human ovarian carcinoma xenografts. Eur J Cancer 1996, 32A (Suppl. 1): Abst 280.
7. Teicher, B.A., Holden, S.A., Ara, G. el al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti angiogenic agents. Int J Cancer 1994, 57: 920-5.
8. Fenaux, P. Effects of all-trans-retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993, 82: 3241-9.
9. 2bin patients with multiple myeloma responding to conventional induction chemotherapy. New Engl J Med 1990, 322: 1430-4.
10. Diaz-Rubio, E., Jimeno, J., Camps, C. Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: Activity in liver metastasis. Cancer Invest 1992, 10 (4): 257-62.
11. Fernández-Puentes, J.L., Rinehart, K.L. Marine-derived pharmaceuticals. Pharm Man Int 1995, 17-9.
12. Rinehart, K.L. Prospects for pharmaceuticals from marine organisms. Proc Jpn Conf Marine Biol 1995.
13. Brusca, B.C., Brusca, G.J. Invertebrates. Sinauer Associates, Inc.: Sunderland, MA 1990, 3.
14. Bergmann, W., Feeney, R. Contributions to the study of marine products. The nucleosides of sponges. III. Spongothymidine and spongouridine. J Org Chem 1955, 20: 1501-7.
15. Wolf, S.N., Marion, J., Stein, R.S, et al. High dose cytosine arabinoside and daunorubicin as consolidation therapy for acute non lymphoblastic leukemia in first remission: A pilot study. Blood 1985, 65 (6): 1407-11.
16. Moore, M. Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review. Cancer 1996, 78 (3): 633-7.
17. Guchelaar, H.J., Richel, D.J., van Knapen, A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 1996, 22: 15-31.
18. Rinehart, K.L., Gloer, J.B., Cook, J.C. et al. Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate. J Am Chem Assoc 1981, 103: 1857-9.
19. Crews, C.M., Collins, J.L., Lane, W.S. et al. GTP-dependent binding of the antiproliferative agent didemnin to the elongation factor 1α. J Biol Chem 1994, 269 (22): 15411-4.
20. Kucuk, O., Young, M., Hochster, H. et al. Phase II trial of didemnin B in previously treated non Hodgkin lymphoma (NHL): An Eastern Cooperative Group (ECOG) study (EST 1489). Proc Am Soc Clin Oncol (May 18-21, Philadelphia) 1996, 15: Abst 1269.
21. Sakai, R., Rinehart, K.N., Kishore, V. et al. Structure activity relationship for the didemnins. J Med Chem 1996, 39: 2819-34.
22. Urdiales, J.L., Morala, P., Nuñez de Castro, I., Sánchez-Jiménez, F. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 1996, 102: 31-7.
23. Dorr, R.T., Shipp, N.G., Lee, K.M. Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro. Anticancer Drugs 1991, 2: 27-33.
24. Faircloth, G., Rinehart, K.L., Nuñez de Castro, I., Jimeno, J. Dehydrodidemnin B: A new marine derived antitumor agent with activity against experimental tumor models. Proc 9th NCI/EORTC Symp New Drugs Cancer Ther (March 12-15, Amsterdam) 1996, 7 (Suppl. 1): Abst 111.
25. Pettit, G.R., Kamano, Y., Herald, C.L. et al. Isolation and structure of bryostatin-1. J Am Chem Soc 1982, 104: 6846-8.
26. Hennings, H., Blumberg, P.M., Pettit, G.R. et al. Bryostatin-1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in Sencar mouse skin. Carcinogenesis 1987, 9: 1343-6.
27. Prendiville, J., Crowther, D., Thatcher, N. et al. A phase I study of intravenous bryostatin-1 in patients with advanced cancer. Br J Cancer 1993, 68: 418-24.
28. Philips, P.A., Rea, D., Thavasu, P. et al. Phase I study with bryostatin-1: Assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. J Natl Cancer Inst 1993, 85: 1812-8.
29. Varterasian, M., Eilender, D., Mohammad, R. et al. Phase I trial with bryostatin 1 in relapsed lymphoma and CLL. Proc Am Soc Clin Oncol (May 18-21, Philadelphia) 1996, 15: Abst 1526.
30. Toppmeyer, D., Bryant, M., Kinchla, N. et al. A phase I clinical and pharmacodynamic study of all-trans retinoic acid and bryostatin-1 in patients with advanced malignancies. Proc Am Soc Clin Oncol (May 18-21, Philadelphia) 1996, 15: Abst 1530.
31. Mross, K., Fiebig, H.H., Berdel, W. et al. Clinical and pharmacokinetic phase I study with LU103793 administered as 24-hour infu-sion. Proc Am Soc Clin Oncol (May 18-21, Philadelphia) 1996, 15: Abst 1533.
32. Hamann, M.T., Scheuer, P.J., Kahalalide, F. A bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp. J Am Chem Soc 1993, 115: 5825-6.
33. Gravalos, L.C., de Quesada, T.G., Faircloth, G., Jimeno, J. Identification of novel marine natural products with antineoplastic activity. Ann Oncol 1994, 5 (Suppl. 8): Abst P933.
34. Faircloth, G., Scheuer, P., Avila, J. et al. A new marine depsipeptide with selective activity against solid tumor models. Proc 9th NCI/ EORTC Symp New Drugs Cancer Ther (March 12-15, Amsterdam) 1996, 7 (Suppl. 1): Abst 110.
35. Garcia-Rocha, M., Bonay, P., Avila, J. The antitumoral compound kahalalide F acts on cell lysosomes. Cancer Lett 1996, 99: 43-50.
36. D'lncalci, M., Erba, E., Farelta, M. et al. New drugs of marine origin. Proc 9th NCI/EORTC Symp New Drugs Cancer Ther (March 12-15, Amsterdam), 1996, 7( Suppl. 1): Abst 034.
37. Rinehart, K.L., Holt, T.G., Fregeau, N.L. et al. Ecteinascidins 729, 743, 745, 759A, 759B and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J Org Chem 1990, 55 (15): 4515-6.
38. Guan, Y., Sakai, R., Rinehart, K.L., Wang, A.H.J. Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata. J Org Chem 1993, 10 (5): 793-818.
39. Reid, J.M., Walker, D.L., Ames, M.M. Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. Cancer Chemother Pharmacol 1996, 38: 329-34.
40. Sakai, R., Rinehart, K.L., Guan, Y., Wang, A.H.J. Additional antitumor ecteinascidins from a Caribbean tunicate: Crystal structure and activities in vivo. Proc Natl Acad Sci USA 1992, 89: 11456-60.
41. Guan, Y., Sakai, R., Rinehart, K.L., Wang, A.H.J. Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata. J Biomol Struct Dyn 1993, 10: 793-818.
42. Rinehart, K.L., Gravalos, L.G., Faircloth, G., Jimeno, J. Ecteinascidin (ET-743): Preclinical antitumor development of a marine derived natural product. Proc Am Assoc Cancer Res (March 18-22, Toronto) 1995, 36: Abst 2322.
43. Hanauske, A.R., Hanauske, U., Von Hoff, D.D. The human tumor cloning assay in cancer research and therapy. Curr Probl Cancer Res 1985, 9 (12): 4-66.
44. Eckhart, G., Degen, D., Faircloth, G., Jimeno, J., Von Hoff, D.D. Activity of ecteinascidins, a novel marine compound against human tumor colony forming units. Proc Am Assoc Cancer Res (April 20-24, Washington) 1996, 37: Abst 2701.
45. Eckhardt, S.G., Degen, D., Ortiz, V. et al. In vitro studies of a novel marine cytotoxic, ecteinascidin (ET-743). Ann Oncol 1996, 7 (Suppl. 5): Abst 632P,
46. Kaufmann, S.H., Peereboom, D., Buckwaller, C.A. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996, 88(11): 734-41.
47. Pommier, Y., Kohlhagen, G., Mazumber, A. DNA sequence and structure selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin-743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Proc Am Assoc Cancer Res (April 20-24, Washington) 1996, 37: Abst 2789.
48. Broggini, M., D'lncalci, M. Modulation of transcription factor-DNA interactions by anticancer drugs. Anti-Cancer Drug Des 1994, 9: 373-87.
49. Garcia-Rocha, M.A., Gravalos, M.D., Avila, J. Characterisation ot antimitotic products from marine organisms that disorganise the microtubule network: Ecteinascidin 743, isohomohalichondrin-B and LL-15. Br J Cancer 1996, 73: 875-83.
50. Erba, E., Balconi, G., Faretta, M. et al. Cell cycle phase perturbations induced by new natural marine compounds. Proc 9th NCI/EORTC Symp New Drugs Cancer Ther (March 12-15, Amsterdam) 1996, Abst 283.
51. Iglesias, C., Guinea, J. Aquaculture of tunicates producing anticancer compounds: Reproduction and larval development of Ecteinascidia turbinata. Proc Aquae 1995, Abst 260.
52. Faircloth, G., Rinehart, K.L., Avila, J. et al. ET-743: A marine compound with significant in vivo activity in early and advanced breast cancer models. Proc Int Symp Changes Treat Breast Cancer (June 5-6, Madrid) 1995, Abst 1.
53. Hendricks, H.R., Drees, M., Giavazzi, R. et al. High antitumor activity of ET-743 in human tumor xenograft models. Proc Am Assoc Cancer Res (April 20-24, Washington) 1996, 37: Abst 2653.
54. Hendricks, H.R., Fiebig, H.H., Giavazzi, R., Langdon, S.P., Jimeno, J. ET-743, a marine natural product with high antitumor activity in human tumor xenograft models. Ann Oncol 1996, 7 (Suppl. 1): Abst P109.
55. Giavazzi, R., Valoti, G., Faircloth, G. et al. Antitumor activity of ET-743: A marine natural product on human ovarian carcinoma xenografts. Proc 1st Eur Symp Ovarian Cancer 1996, Abst 04.
56. Joint Steering Committee of the EORTC and the CRC. General guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. Eur J Cancer 1990, 26 (3): 411-4.
57. Mirsalis, J.C., Schindler-Horvat, J.E., Tomaszewski, J.E. et al. Preclinical toxicology studies of ecteinascidin 743. Proc Am Soc Clin Oncol (May 18-21, Philadelphia) 1996, 37: Abst 2556.
58. Tomaszewski, J.E., Donohue, S.J. et al. Preclinical toxicity of ecteinascidin 743. Proc Ann PAMM/EORTC Meeting (November, Newcastle) 1995.
59. Hillebrand, M.J.X., Rosing, H., Henrar, R.E.C. et al. High performance liquid chromatographic analysis of the new experimental antitumor drug ecteinascidin 743 in human plasma. Proc 9th NCI/ EORTC Symp New Drugs CancerTher (March 12-15, Amsterdam) 1996, 7 (Suppl. 1): Abst 165.
60. Cocchiaro, C., Nelson, C., Haupt, A., Janssen, B., Barlozzari, T. Induction of apoptosis in vitro and in vivo by treatment with LU103793. Proc Am Soc Clin Oncol (May 18-21, Philadelphia) 1996, 37: Abst 2715.
61. Baillie, C.T., Winslet, M.C., Bradley, N.J. Tumor vasculature - A potential therapeutic target. Br J Cancer 1995, 72: 257-67.
62. Chaplin, D.J., Pettit, G.R., Parkins, C.S., Hill, A. Antivascular approaches to solid tumor therapy: Evaluation of tubulin binding agents. Br J Cancer 1996, in press.
63. Hennequin, C., Giocanti, N., Favaudon, V. Interaction of ionizing radiation with paclitaxel and docetaxel in HeLa and SQ20B cells. Cancer Res 1996, 56: 1842-50.
64. Connors, T.A. Is there a future for cancer chemotherapy? Ann Oncol 1996, 7: 445-52.
65. Holmberg, L., Baum, M. Work on your theories! Nat Med 1996, 2 (8): 844-6.